, /PRNewswire/ -- Sen-Jam Pharmaceutical, a leading innovator in the development of therapeutics for age-related diseases, is pleased to announce the upcoming completion of the clinical trial for its groundbreaking therapeutic, SJP-002C, in . SJP-002C targets Upper Respiratory Infections (URIs), including COVID-19, and is poised to revolutionize the treatment landscape by providing a radically safe, potent, and widely accessible solution to a global market in dire need of effective options. The global pandemic has highlighted the inadequacies of current treatments for URIs and COVID-19.
Existing therapies often come with significant side effects, high costs, and limited accessibility, leaving millions of patients without adequate care. The market is ripe for a disruptor, and SJP-002C is positioned to fill this critical gap. " ," said , Co-Founder and CEO of Sen-Jam Pharmaceutical.
" " SJP-002C hopes to demonstrate significant efficacy in reducing inflammation in patients with COVID-19 during its Phase 2 clinical trial, conducted in collaboration with principal investigators Dr. and Dr. Alexander Limkakeng from .
A preliminary showed a significant reduction in viral load as well as reduction of symptom severity and duration resulting from the innovative combination of two anti-inflammatory agents. With patents filed in 15 countries and a patented streamlined manufacturing process developed in partnership with , SJP-002C is well-positioned for rapid global deployment upon regul.
